Amgen Inc. $AMGN Shares Sold by Capital Group Private Client Services Inc.

Capital Group Private Client Services Inc. lowered its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 77.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 69,412 shares of the medical research company’s stock after selling 236,525 shares during the period. Capital Group Private Client Services Inc.’s holdings in Amgen were worth $19,588,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Capital Group Investment Management PTE. LTD. increased its holdings in shares of Amgen by 93.4% during the third quarter. Capital Group Investment Management PTE. LTD. now owns 11,732 shares of the medical research company’s stock valued at $3,311,000 after purchasing an additional 5,666 shares during the period. Bank of Montreal Can grew its position in Amgen by 5.3% in the 3rd quarter. Bank of Montreal Can now owns 1,063,079 shares of the medical research company’s stock valued at $300,001,000 after buying an additional 53,566 shares in the last quarter. Legal & General Group Plc increased its stake in Amgen by 5.0% during the 3rd quarter. Legal & General Group Plc now owns 3,716,957 shares of the medical research company’s stock valued at $1,048,925,000 after buying an additional 177,325 shares during the period. Pinkerton Wealth LLC raised its position in shares of Amgen by 11.5% during the 3rd quarter. Pinkerton Wealth LLC now owns 17,976 shares of the medical research company’s stock worth $5,073,000 after buying an additional 1,850 shares in the last quarter. Finally, Banque Cantonale Vaudoise lifted its stake in shares of Amgen by 2.3% in the 3rd quarter. Banque Cantonale Vaudoise now owns 17,333 shares of the medical research company’s stock worth $4,892,000 after acquiring an additional 392 shares during the period. Institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently commented on AMGN. DZ Bank raised their price objective on shares of Amgen from $335.00 to $364.00 in a research note on Monday, November 10th. The Goldman Sachs Group lifted their price target on Amgen from $403.00 to $415.00 and gave the company a “buy” rating in a research report on Wednesday, February 4th. Truist Financial boosted their price objective on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a research note on Thursday, January 8th. Citigroup lifted their target price on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Finally, BMO Capital Markets boosted their price target on shares of Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $354.17.

Amgen Price Performance

AMGN stock opened at $376.97 on Tuesday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a one year low of $261.43 and a one year high of $391.29. The firm has a market capitalization of $203.21 billion, a PE ratio of 26.49, a P/E/G ratio of 3.67 and a beta of 0.45. The firm has a 50-day moving average of $354.21 and a two-hundred day moving average of $323.38.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion for the quarter, compared to the consensus estimate of $9.46 billion. During the same period last year, the firm posted $5.31 earnings per share. The firm’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be issued a $2.52 dividend. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. Amgen’s dividend payout ratio is presently 70.84%.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.